Skip to Content

Publications Search - Abstract View

Title: Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Authors: Peterlongo P,  Chang-Claude J,  Moysich KB,  Rudolph A,  Schmutzler RK,  Simard J,  Soucy P,  Eeles RA,  Easton DF,  Hamann U,  Wilkening S,  Chen B,  Rookus MA,  Schmidt MK,  van der Baan FH,  Spurdle AB,  Walker LC,  Lose F,  Maia AT,  Montagna M,  Matricardi L,  Lubinski J,  Jakubowska A,  Gómez Garcia EB,  Olopade OI,  Nussbaum RL,  Nathanson KL,  Domchek SM,  Rebbeck TR,  Arun BK,  Karlan BY,  Orsulic S,  Lester J,  Chung WK,  Miron A,  Southey MC,  Goldgar DE,  Buys SS,  Janavicius R,  Dorfling CM,  van Rensburg EJ,  Ding YC,  Neuhausen SL,  Hansen TV,  Gerdes AM,  Ejlertsen B,  Jřnson L,  Osorio A,  Martínez-Bouzas C,  Benitez J,  Conway EE,  Blazer KR,  Weitzel JN,  Manoukian S,  Peissel B,  Zaffaroni D,  Scuvera G,  Barile M,  Ficarazzi F,  Mariette F,  Fortuzzi S,  Viel A,  Giannini G,  Papi L,  Martayan A,  Tibiletti MG,  Radice P,  Vratimos A,  Fostira F,  Garber JE,  Donaldson A,  Brewer C,  Foo C,  Evans DG,  Frost D,  Eccles D,  Brady A,  Cook J,  Tischkowitz M,  Adlard J,  Barwell J,  Walker L,  Izatt L,  Side LE,  Kennedy MJ,  Rogers MT,  Porteous ME,  Morrison PJ,  Platte R,  Davidson R,  Hodgson SV,  Ellis S,  Cole T,  EMBRACE,  Godwin AK,  Claes K,  Van Maerken T,  Meindl A,  Gehrig A,  Sutter C,  Engel C,  Niederacher D,  Steinemann D,  Plendl H,  Kast K,  Rhiem K,  Ditsch N,  Arnold N,  Varon-Mateeva R,  Wappenschmidt B,  Wang-Gohrke S,  Bressac-de Paillerets B,  Buecher B,  Delnatte C,  Houdayer C,  Stoppa-Lyonnet D,  Damiola F,  Coupier I,  Barjhoux L,  Venat-Bouvet L,  Golmard L,  Boutry-Kryza N,  Sinilnikova OM,  Caron O,  Pujol P,  Mazoyer S,  Belotti M,  GEMO Study Collaborators,  Piedmonte M,  Friedlander ML,  Rodriguez GC,  Copeland LJ,  de la Hoya M,  Segura PP,  Nevanlinna H,  Aittomäki K,  van Os TA,  Meijers-Heijboer HE,  van der Hout AH,  Vreeswijk MP,  Hoogerbrugge N,  Ausems MG,  van Doorn HC,  Collée JM,  HEBON,  Olah E,  Diez O,  Blanco I,  Lazaro C,  Brunet J,  Feliubadalo L,  Cybulski C,  Gronwald J,  Durda K,  Jaworska-Bieniek K,  Sukiennicki G,  Arason A,  Chiquette J,  Teixeira MR,  Olswold C,  Couch FJ,  Lindor NM,  Wang X,  Szabo CI,  Offit K,  Corines M,  Jacobs L,  Robson ME,  Zhang L,  Joseph V,  Berger A,  Singer CF,  Rappaport C,  Kaulich DG,  Pfeiler G,  Tea MK,  Phelan CM,  Greene MH,  Mai PL,  Rennert G,  Mulligan AM,  Glendon G,  Tchatchou S,  Andrulis IL,  Toland AE,  Bojesen A,  Pedersen IS,  Thomassen M,  Jensen UB,  Laitman Y,  Rantala J,  von Wachenfeldt A,  Ehrencrona H,  Askmalm MS,  Borg Ĺ,  Kuchenbaecker KB,  McGuffog L,  Barrowdale D,  Healey S,  Lee A,  Pharoah PD,  Chenevix-Trench G,  KConFab Investigators,  Antoniou AC,  Friedman E
Journal: Cancer Epidemiol Biomarkers Prev
Date: 2015 Jan
Branches: CGB
PubMed ID: 25336561
PMC ID: PMC4294951
Abstract: BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. METHODS: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. RESULTS: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. CONCLUSION: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. IMPACT: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308-16. ©2014 AACR.